Concentrations of most antiseizure medications (ASMs) were similar in maternal and umbilical cord blood at delivery in pregnant women with epilepsy in a new study, which researchers said suggests ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

DONATION. AND HERE’S MARIA WILSON WITH MORE ABOUT IT. POWER RED PROCEDURE IS AN OPPORTUNITY FOR YOU TO MAXIMIZE YOUR DONATION, THE RED CROSS SAYS, BY DONATING JUST YOUR RED BLOOD CELLS, YOU CAN SAVE ...

Elaine Haynes from KaloCyte, maker of essential ingredients for a new human blood substitute, talks about the final steps to get the product in troops hands. Trump promises 5,000 US troops to an ally ...

ALTAMONTE SPRINGS, Fla.--(BUSINESS WIRE)--In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower ...

Expertise alone doesn’t close deals. Success comes from connecting your capabilities to what buyers truly value. This can be achieved through a structured sales process. A structured sales process is ...

The New York Blood Center Enterprises and the Chan Zuckerberg Biohub are collaborating to derive induced pluripotent stem cell lines from cord blood, using NYBCe’s inventory of over 30,000 units, ...

Adding a pooled umbilical cord blood product to HLA-matched single-unit cord blood transplants resulted in 96% disease-free survival in acute leukemia and other hematologic malignancies. No grade 3 or ...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the ...

A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A Phase II clinical trial of patients ...

A phase 2 study published in the Journal of Clinical Oncology shows that a stem cell product called dilanubicel safely enabled umbilical cord blood transplants in 28 patients SEATTLE — April, 27, 2026 ...

Between March 2022 and July 2025, we enrolled 28 patients with hematologic malignancies in this single-center phase II trial. The infusion of a matched single CB unit was followed by a target dose of ...